HOME   SITE MAP   CONTACT US

 Back

SCYNEXIS ANNOUNCES NEW BOARD CHAIRMAN AND NEW BOARD MEMBER APPOINTMENTS OF WELL-KNOWN PHARMACEUTICAL EXECUTIVES

RESEARCH TRIANGLE PARK, North Carolina (MARCH 28, 2006) - SCYNEXIS, Inc., a chemistry-focused drug discovery and development company, today announced that Dr. Pamela Kirby has been selected as the new Chairman of the Company’s Board of Directors replacing Mr. Philip Chauveau, who is retiring as Board Chairman but will remain as a Board Member. Dr. Kirby, the former Chief Executive Officer of Quintiles Transnational Corp., has been a Board Member since December 2004.

The Company also announced the appointment of Mr. Patrick Langlois, former Aventis Vice Chairman and Chief Financial Officer, to replace Mr. Laurent Arthaud, a founding Board Member who will leave the Board.

"SCYNEXIS is excited to have these two well-known industry executives on our Board,” said Yves Ribeill, SCYNEXIS President and Chief Executive Officer. “Pamela Kirby brings her extensive pharmaceutical development and leadership experience to her role as Chairman and is, of course, well known here in North Carolina’s Research Triangle Park due to her former CEO position with Quintiles. Patrick Langlois brings a global reputation in the financial area of the pharmaceutical industry from his previous Aventis Vice Chairman and Chief Financial Officer responsibilities."

"As SCYNEXIS grows and enters into more product development partnerships, we will benefit from the depth of pharmaceutical industry experience of Dr. Kirby and Mr. Langlois. At the same time, we are deeply appreciative of Phil Chaveau’s leadership as Chairman and Laurent Arthaud’s involvement as a Board Member during the formative years of our company," Dr. Ribeill said.

"These Board appointments underscore our company’s commitment to continue our growing presence in drug discovery and to engage in more global research and development partnerships," Ribeill said.

Pamela J. Kirby, Ph.D.
Dr. Kirby brings over 25 years experience in the pharmaceutical and biotechnology industries. Most recently, Dr. Kirby was the Chief Executive Officer of Quintiles Transnational Corporation, a provider of integrated product development and commercial solutions to the pharmaceutical and biotechnology industries. Dr. Kirby is currently a non-executive Director of Smith and Nephew plc, Oscient Pharmaceuticals Corporation, Informa plc and Curalogic A/S. Dr. Kirby began her career at Astra AB (now AstraZeneca), rising through several senior management positions before becoming Managing Director of the UK and Ireland subsidiaries in 1988 and being named Vice President, Corporate Strategy, Marketing and Business Development, in 1994. From there, she became Commercial Director at British Biotech plc (now Vernalis) and then Director of Global Strategic Marketing and Business Development in the pharmaceutical division of Hoffman-La Roche Ltd. She has a BSc in pharmacology and a Ph.D. in clinical pharmacology.

Patrick J. Langlois
Mr. Patrick Langlois is the General Partner of PJL Conseils, a consulting firm, since March 1st, 2005. He served as Vice Chairman of Aventis’ Management Board and Chief Financial Officer from May 2002 to September 2004 and Executive Vice President and Chief Financial Officer of Aventis S.A. from December 1999 to May 2002. At Aventis, Patrick Langlois was responsible for finance and corporate development functions as well as three global businesses: chemicals, protein therapeutics and animal health. Prior to joining Aventis, he was employed by the Rhône-Poulenc Group from 1975 to 1999, most recently as Chief Financial Officer and Member of the Executive Committee. Patrick Langlois received a License degree from the University of Rennes in 1967, a Ph.D. degree in Economics from the University of Rennes and was awarded a Diploma in Higher Banking Studies.

About SCYNEXIS
SCYNEXIS is a chemistry-focused drug discovery and development company with its headquarters located in Research Triangle Park, North Carolina. SCYNEXIS offers a full spectrum of discovery and development transactions from fee-for-service projects to risk-sharing collaborations that could result in SCYNEXIS milestones, royalties and product rights. We currently have product collaborations in the anti-fungal, anti-HIV, anti-HCV and animal health areas.

SCYNEXIS fee-for-service capabilities range from concept to clinic, with services performed by teams integrating computational chemistry, medicinal chemistry, bioanalysis and process chemistry. SCYNEXIS teams use powerful, proprietary technologies such as the HEOS® Software Suite, MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to optimize lead molecules for candidate selection. SCYNEXIS process chemistry and bioanalytical departments operate under current GMP/GLP guidelines and have established a strong track record of success. SCYNEXIS tailors its teams to be especially effective in moving customer projects from the discovery phase to clinical proof of concept.

Dr. Yves Ribeill will present a SCYNEXIS business overview at the BIO 2006 Business Forum in Chicago.

For more information, please go to www.scynexis.com

SCYNEXIS Media Contact:
Rick Rountree
Rick Rountree Communications
(+1) 919-878-1144
rick@rickrountree.com

SCYNEXIS Market Development Contact:
Terry Marquardt
(+1) 919-544-8600
terry.marquardt@scynexis.com